Skip to main content
ELUT
NASDAQ Life Sciences

Elutia Inc. Adopts New Inducement Equity Plan, Authorizing 2 Million Shares for New Hires

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.17
Mkt Cap
$49.96M
52W Low
$0.5
52W High
$3.46
52W Position info
134% above low
Off High info
66% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ELUT has more than doubled off its 52-week low of $0.5.

Summary

Elutia Inc. adopted a new 2026 Inducement Award Plan, authorizing 2,000,000 shares for equity grants to new employees, potentially diluting existing shareholders by approximately 4.68%.


Key Events · Financing and Capital Events · ELUT

  • New Inducement Award Plan Adopted

    The Board of Directors adopted the Elutia Inc. 2026 Inducement Award Plan on March 3, 2026.

  • Shares Authorized for Issuance

    A maximum of 2,000,000 shares of Class A common stock may be issued under the plan. If all authorized shares were issued, this would represent a potential dilution of approximately 4.68%.

  • Purpose to Attract Talent

    The plan's purpose is to induce individuals to enter employment and to attract, retain, and motivate persons expected to make important contributions to the company.

  • No Stockholder Approval Required

    Awards under the plan are granted as a material inducement to new employment, meaning stockholder approval was not required per Nasdaq Rule 5635(c)(4).


Analysis · ELUT · Life Sciences

Elutia Inc. has adopted a new equity inducement plan, authorizing the issuance of up to 2,000,000 shares of Class A common stock for new employees. This plan is designed to attract and retain key talent by offering equity ownership opportunities, which is a positive strategic move for growth. However, if all authorized shares were issued, this would represent a potential dilution of approximately 4.68% based on the current outstanding shares. This follows a recent positive development where the company regained full compliance with Nasdaq's minimum bid price and market value requirements on March 4, 2026.

At the time of this filing, ELUT was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50M. The 52-week trading range was $0.50 to $3.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELUT - Latest Insights

ELUT
Jul 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9351
Real-time Price: $0.9333 info
Change: -$0.0018 (-0.19%) info
Market Cap: $40.451M info
ELUT
Jun 16, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.9333 info
Change: -$0.0167 (-2%) info
Market Cap: $40.451M info
ELUT
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.9333 info
Change: -$0.0967 (-9%) info
Market Cap: $40.451M info
ELUT
May 15, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.9333 info
Change: -$0.0967 (-9%) info
Market Cap: $40.451M info
ELUT
May 14, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.9333 info
Change: -$0.0667 (-7%) info
Market Cap: $40.451M info